We serve Chemical Name:L-glucitol CAS:6706-59-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:L-glucitol
CAS.NO:6706-59-8
Synonyms:L-Glucitol;L-Sorbitol;Gulitol;D-Gulitol;(2R,3S,4S,5S)-hexane-1,2,3,4,5,6-hexol
Molecular Formula:C6H14O6
Molecular Weight:182.17200
HS Code:2905499000
Physical and Chemical Properties:
Melting point:166-168ºC
Boiling point:494.9ºC at 760 mmHg
Density:1.596g/cm3
Index of Refraction:1.597
PSA:121.38000
Exact Mass:182.07900
LogP:
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like L-Glucitol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(2R,3S,4S,5S)-hexane-1,2,3,4,5,6-hexol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,L-Sorbitol Use and application,L-Glucitol technical grade,usp/ep/jp grade.
Related News: At the same time, because the profits of a single variety of characteristic APIs do not have long-term growth, companies need more product reserves. L-glucitol manufacturer As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL. L-glucitol supplier INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment. L-glucitol vendor As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL. L-glucitol factory At the same time, because the profits of a single variety of characteristic APIs do not have long-term growth, companies need more product reserves.
